

Subj. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Docket Number <b>107.823.129</b>	Application Number <b>09/376,604</b>
				Applicant <b>Madiyalakan et al.</b>	
Sheet	<b>1</b>	OF	<b>8</b>	Filing Date <b>August 18, 1999</b>	Group Art Unit <b>1642</b>

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GJ KAC	3,855,689	02/11/1975	Goldenberg	195	1.7	
	4,331,647	05/25/1982	Goldenberg	424	1	
	5,053,224	10/01/1991	Koprowski et al.	424	85.8	
	5,165,922	11/24/1992	Hellstrom et al.	424	85.8	

Foreign Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
GJ KAC	0 234 122 A2	09/02/1987	EP	—	—	
✓	0 308 208 A1	03/22/1989	EP	—	—	
✓	WO 89/05140	06/15/1989	PCT	—	—	
✓	WO 88/03954	06/02/1988	PCT	—	—	
✓	WO 87/00053	01/15/1987	PCT	—	—	

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
GJ KAC	Abbas AK et al., "Antigen presentation by B lymphocytes," <i>Antigen Presenting Cells: Diversity, Differentiation, and Regulation</i> 269-279 (1988)
✓	Adams S et al., "Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings," <i>Eur J Nucl Med.</i> 25(9):1277-83 (1998)
✓	Alzona M et al., "IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells," <i>J Immunol.</i> 154(1):9-16 (1995)
✓	American Cancer Society, "Cancer Facts and Figures," Atlanta, GA: American Cancer Society (1995)
✓	Andersson K et al., "Modulation of antigen-antibody complexations by immunoglobulins," <i>Scand J Immunol.</i> 42(4):407-17 (1995)
✓	Bachmann MF et al., "Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen," <i>Eur J Immunol.</i> 24(10):2567-70 (1994)
✓	Barnd DL et al., "Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells," <i>Proc Natl Acad Sci U S A.</i> 86(18):7159-63 (1989)
✓	Bartoloni C et al., "Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients," <i>Oncology</i> 50(1):27-34 (1993)
✓	Bast RC Jr. et al., "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer," <i>New England J. Med.</i> 309(15):883-7 (1983)
✓	Baum RP et al., "Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma," <i>Cancer</i> 73(3 Suppl):1121-5 (1994)

EXAMINER <i>GJ KAC</i>	DATE CONSIDERED <i>11/27/05 8/20/07</i>
---------------------------	--

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Sub. For, PTO-1449				Docket Number 107.823.129	Application Number 09/376,604
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Madiyalakan et al.	
Sheet	2	OF	8	Filing Date August 18, 1999	Group Art Unit 1642

<i>fw</i>	<i>HAK</i>	Bernard NF et al., "Possible Role for Specific Surface Immunoglobulin In Antigen Presentation," <i>Antigen Presenting Cells: Diversity, Differentiation, and Regulation</i> 291-300 (1988)
		Boon T et al., "Tumor antigens recognized by T lymphocytes," <i>Annu Rev Immunol.</i> 12:337-65 (1994)
		Brakenhoff RH et al., "Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer," <i>Cancer Immunol Immunother.</i> 40(3):191-200 (1995)
		Bretscher PA et al., "Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major," <i>Science</i> 257(5069):539-42 (1992)
		Brockmeyer NH et al., "Immunomodulation of cimetidine in healthy volunteers," <i>Klin Wochenschr.</i> 67(1):26-30 (1989)
		Bouige P et al., "Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes," <i>Hybridoma</i> 9(6):519-26 (1990)
		Bukowski RM et al., "Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies," <i>J Immunother.</i> 10(6):432-9 (1991)
		Canevari S et al., "Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody," <i>J Natl Cancer Inst.</i> 87(19):1463-9 (1995)
		Chang CT et al., "Circular dichroic analysis of protein conformation: inclusion of the beta-turns," <i>Anal Biochem.</i> 91(1):13-31 (1978)
		Chatterjee MB et al., "Idiotypic antibody immunotherapy of cancer," <i>Cancer Immunol Immunother.</i> 38(2):75-82 (1994)
		Chester SJ et al., "Improved detection of the early stages of colon cancer by determining both free circulating and immune complex-bound antigens reactive with monoclonal antibody," <i>Cancer Res.</i> 54(15):3974-8 (1994)
		Cheung NK et al., "Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival," <i>Cancer Res.</i> 54(8):2228-33 (1994)
		Clarke-Pearson DL et al., "Palliative surgery for epithelial ovarian cancer," In Rub SC, Sutton GP eds. <i>Ovarian Cancer</i> New York: McGraw-Hill, Inc. 1993: 351-364
		Crum ED, "Effect of cisplatin upon expression of in vivo immune tumor resistance," <i>Cancer Immunol Immunother.</i> 36(1):18-24 (1993)
		Detoin A et al., "A new liquid phase actinometer: Quantum yield and photo-cidnp study of phenylglyoxylic acid in aqueous solution," <i>J. Photochem.</i> 33:237-255 (1985)
		DiLeo AJ et al., "High resolution removal of virus from protein solutions using a membrane of unique structure," <i>Biotechnology</i> 10(2):182-8 (1992)
		DiLeo AJ et al., "Size exclusion removal of model mammalian viruses using a unique membrane system, Part II: Module qualification and process simulation," <i>Biologicals</i> 21(3):287-96 (1993)
		DiLeo AJ et al., "Size exclusion removal of model mammalian viruses using a unique membrane system, Part I: Membrane qualification," <i>Biologicals</i> 21(3):275-86 (1993)

EXAMINER <i>Garrett R. Schubert</i>	DATE CONSIDERED 11/27/05 8/20/07
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Sub1. For, PTO-1449

INFORMATION DISCLOSURE  
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

3

OF

8

Docket Number  
107.823.129Application Number  
09/376,604Applicant  
Madiyalakan et al.Filing Date  
August 18, 1999Group Art Unit  
1642

<i>AN</i>	Dorai, H et al., "Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function," <i>Hybridoma</i> 10:211-7 (1991)
<i>DUR</i>	Dohlsten M et al., "Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy," <i>Proc Natl Acad Sci U S A.</i> 91(19):8945-9 (1994)
<i>NAC</i>	Dohlsten M et al., "Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo," <i>Proc Natl Acad Sci U S A.</i> 92(21):9791-5 (1995)
<i>↓</i>	Donnerstag B et al., "Immunological profile of patients with ovarian cancer under immunostimulation with murine monoclonal antibodies," <i>International J. of Oncology</i> 6:853-858 (1995)
<i>DUR</i>	Durrant LG et al., "Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7," <i>Cancer Res.</i> 54(18):4837-40 (1994)
<i>NAC</i>	Ehrke MJ et al., "Effects of anticancer drugs on the immune system in humans," <i>Semin Oncol.</i> 16(3):230-5 (1989)
<i>↓</i>	Engvall E and Perlman P, "Enzyme-linked immunosorbent assay (ELISA), Quantitative assay of immunoglobulin G," <i>Immunochemistry</i> 8:871 (1971)
<i>↓</i>	Fagerberg J et al., "Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?," <i>Cancer Immunol Immunother.</i> 37(4):264-70 (1993)
<i>↓</i>	Fagerberg J et al., "Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?," <i>Cancer Immunol Immunother.</i> 38(3):149-59 (1994)
<i>↓</i>	Fagerberg J et al., "Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes," <i>Cancer Res.</i> 55(9):1824-7 (1995)
<i>↓</i>	Fendrick JL et al., "Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line," <i>Tumour Biol.</i> 14(5):310-8 (1993)
<i>↓</i>	Gadducci A et al., "Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study," <i>Gynecol Oncol.</i> 58(1):42-7 (1995)
<i>↓</i>	Gallagher G and Al-Azzawi F, "Adoptive immunotherapy of experimental ovarian cancer using activated human monocytes and the human monoclonal antibody, anti-14C1," <i>Intl J of Oncology</i> 5:253-258 (1994)
<i>↓</i>	Gallagher G et al., "Multiple epitopes of the human ovarian cancer antigen 14C1 recognised by human IgG antibodies: their potential in immunotherapy," <i>Br J Cancer</i> 64(1):35-40 (1991)
<i>↓</i>	Geffner JR et al., "Activation of human neutrophils and monocytes induced by immune complexes prepared with cationized antibodies or antigens," <i>Clin Immunol Immunopathol.</i> 69(1):9-15 (1993)
<i>↓</i>	Goldenberg DM "New developments in monoclonal antibodies for cancer detection and therapy," <i>CA Cancer J Clin.</i> 44(1):43-64 (1994)
<i>↓</i>	Goronzy Jet al., "Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4," <i>J Exp Med.</i> 164(3):911-25 (1986)


EXAMINER	DATE CONSIDERED
<i>Gordon J. Goronzy</i>	<i>1/27/05 8/20/07</i>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Sub. For, PTO-1449				Docket Number 107.823.129	Application Number 09/376,604
				Applicant Madiyalakan et al.	
				Filing Date August 18, 1999	Group Art Unit 1642
Sheet	4	OF	8		

<i>AR</i>	<i>Handgretinger R et al., "A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma," Eur J Cancer. 31A(2):261-7 (1995)</i>
<i>✓</i>	<i>Hariharan K et al., "The induction of cytotoxic T cells and tumor regression by soluble antigen formulation," Cancer Res. 55(16):3486-9 (1995)</i>
<i>✓</i>	<i>Harris JE and Braun DP, "Abnormal Immunoregulation and the tumor dormant state in human cancer," In: Stewart THM, Wheelock eds. Cellular immune mechanisms and tumor dormancy, Boca Raton, Florida: CRC Press 261-276 (1992)</i>
<i>✓</i>	<i>Hoskins PJ et al., "Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy," J Clin Oncol. 10(10):1561-8 (1992)</i>
<i>✓</i>	<i>Hozumi N and Sandhu JS, "Recombinant antibody technology: its advent and advances," Cancer Invest. 11(6):714-23 (1993)</i>
<i>✓</i>	<i>Hayat MA, <u>Colloidal Gold: Principles, Methods, and Applications</u> Vol. 1, San Diego: Academic Press, Inc. 1989</i>
<i>✓</i>	<i>Iannides CG et al., "Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides," J Immunol. 151(7):3693-703 (1993)</i>
<i>✓</i>	<i>Jacoby RO et al., "Characterization of mouse parvovirus infection by in situ hybridization," J Virol. 69(6):3915-9 (1995)</i>
<i>✓</i>	<i>Jensen JL et al., "Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management," Int. J. Biol. Markers 6:1 (1991)</i>
<i>✓</i>	<i>Jerne NK, "Towards a network theory of the immune system," Ann Immunol (Paris) 125C(1-2):373-89 (1974)</i>
<i>✓</i>	<i>Kehoe S, "Cell-mediated immunity and immunotherapy in ovarian cancer (review)," Int'l J of Oncology 6:451-458 (1995)</i>
<i>✓</i>	<i>Khazaie MB et al., "Human immune response to monoclonal antibodies," J Immunother. 15(1):42-52 (1994)</i>
<i>✓</i>	<i>Kim HT et al., "Gamma delta T cell recognition of tumor Ig peptide," J Immunol. 154(4):1614-23 (1995)</i>
<i>✓</i>	<i>Knuth A et al., "T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures," Proc Natl Acad Sci U S A 81(11):3511-5 (1984)</i>
<i>✓</i>	<i>Kobayashi H et al., "Characterization of CA 125 antigen identified by monoclonal antibodies that recognize different epitopes," Clin Biochem. 26(5):391-7 (1993)</i>
<i>✓</i>	<i>Kosmas C et al., "Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer," Cancer 73(12):3000-10 (1994)</i>
<i>✓</i>	<i>Kosmas C et al., "Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens," Br J Cancer 64(3):494-500 (1991)</i>
<i>✓</i>	<i>FT Kreutz and Suresh MR, "Biospecific monoclonal Anti-CA125 X Anti-peroxidase antibodies in the measurement of the ovarian carcinoma antigen," J of Tumor Marker Oncology 10(1): 45-53 (1995)</i>
<i>✓</i>	<i>Lamers CH et al., "Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytosis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes," Int J Cancer 60(4):450-7 (1995)</i>

EXAMINER <i>Gary L. Miller</i>	DATE CONSIDERED <i>11/27/05 8/20/07</i>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	




Sub. For, PTO-1449				Docket Number 107.823.129	Application Number 09/376,604
INFORMATION DISCLOSURE IN AN APPLICATION  (Use several sheets if necessary)				Applicant Madiyalakan et al.	
Sheet	5	OF	8	Filing Date August 18, 1999	Group Art Unit 1642

<i>GJ</i>	<i>KAS</i>	Lanzavecchia A, "Identifying strategies for immune intervention," <i>Science</i> 260(5110):937-44 (1993)
	✓	Lanzavecchia A et al., "Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets," <i>J Exp Med.</i> 167(2):345-52 (1988)
	✓	Livingston Po et al., "Symposium 10: glucosylation defining malignancy. Effect of active immunization with human tumor associated carbohydrate antigens on the immune response and on tumor growth," <i>Proc. Am. Assoc. Cancer Research</i> 36:678 (1995)
	✓	Loevinger, RL et al., <i>MIRD Primer for Absorbed Dose Calculations</i> New York: Society of Nuclear Medicine, 1991
	✓	Lopes LM and Chain BM, "Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen," <i>Eur J Immunol.</i> 22(1):287-90 (1992)
	✓	Madiyalakan R et al., "Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13," <i>Hybridoma</i> 14(2):199-203 (1995)
	✓	Manca F et al., "Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies," <i>J Exp Med.</i> 173(1):37-48 (1991)
	✓	Maraveyas A and Epenetos AA, "Targeted immunotherapy. An update with special emphasis on ovarian cancer," <i>Acta Oncol.</i> 32(7-8):741-6 (1993)
	✓	Martin AC et al., "Modeling antibody hypervariable loops: a combined algorithm," <i>Proc Natl Acad Sci U S A</i> 83:9268-72 (1986)
	✓	Marusic-Galesic S et al., "Cellular immune response to the antigen administered as an immune complex," <i>Immunology</i> . 72(4):526-31 (1991)
	✓	Meier W, "CA 125 based diagnosis and therapy in recurrent ovarian cancer," Abstract. <i>Abstracts of the Eighth International Hamburg Symposium on Tumor Markers</i> Hamburg, Germany 2443 (1995)
	✓	Mitchell MS, <i>Biological Approaches to Cancer Treatment: Biomodulation</i> New York: McGrawHill, Inc., 1993
	✓	Mitchell MS et al., "Biomodulators in cancer treatment," <i>J Clin Pharmacol.</i> 32(1):2-9 (1992)
	✓	Mosmann TR and RL Coffman, "Two types of mouse helper t-cell clone, Review. <i>Immunology Today</i> 8(7 and 8):223-227 (1987)
	✓	Muddukrishna SN et al., "Indirect iodometric procedure for quantation of Sn(II) in radiopharmaceutical kits," <i>Appl. Radial. Isot.</i> 45(3):293-299 (1994)
	✓	Munn DH and Cheung NK "Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma," <i>Cancer Res.</i> 47(24 Pt 1):5600-5 (1987)
	✓	Naramura M et al., "Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma," <i>Cancer Immunol Immunother.</i> 37(5):343-9 (1993)
	✓	National Cancer Institute of Canada, "Canadian Cancer Statistics" Toronto: National Cancer Institute of Canada (1998)
	✓	Nemazee DA and Sato VL, "Enhancing antibody: a novel component of the immune response," <i>Proc Natl Acad Sci U S A.</i> 79(12):3828-32 (1982)

EXAMINER <i>Gary Miller</i>	DATE CONSIDERED <i>14/27/05 8/20/07</i>
--------------------------------	--

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subj. For, PTO-1449				Docket Number 107.823.129	Application Number 09/376,604
INFORMATION DISCLOSURE IN AN APPLICATION  (Use several sheets if necessary)				Applicant Madiyalakan et al.	
Sheet	6	OF	8	Filing Date August 18, 1999	Group Art Unit 1642

<input checked="" type="checkbox"/>	Ohta S et al., "Tumor-associated glycoantigen, sialyl Lewis <sup>x</sup> as a target for bispecific antibody-directed adoptive tumor immunotherapy," <i>Immunol Lett.</i> 44(1):35-40 (1995)
<input checked="" type="checkbox"/>	Ovarian Cancer: Screening, Treatment, and Followup. NIH Consens Statement 12(3):1-30 (1994)
<input checked="" type="checkbox"/>	Ozols, MD, PhD, RF "Biologic Treatment of Human Cancer," <i>Current Problems in Cancer</i> 19(4):186-261 (1995)
<input checked="" type="checkbox"/>	Pederson J et al., "Antibody Modeling: Beyond Homology," <i>Immunomethods</i> 1:126-136 (1992)
<input checked="" type="checkbox"/>	Peralta-Heape M et al., "Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts," <i>Eur J Nucl Med.</i> 18(5):339-45 (1991)
<input checked="" type="checkbox"/>	Pierce SK and LA Casten, "Soluble globular protein antigens covalently coupled to antibodies specific for b cell surface structures are effective antigens both in vitro and in vivo," <i>Antigen presenting cells: diversity, differentiation, and regulation</i> 259-268 (1988)
<input checked="" type="checkbox"/>	Pimm MV, "Circulating antigen: bad or good for immunoscintigraphy?" <i>Nucl Med Biol.</i> 22(2):137-45. Review. (1995)
<input checked="" type="checkbox"/>	Pimm MV et al., "Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments," <i>J Cancer Res Clin Oncol.</i> 119(7):408-14 (1993)
<input checked="" type="checkbox"/>	Pimm MV and Gribben SJ, "Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice," <i>J Cancer Res Clin Oncol.</i> 119(1):41-5 (1992)
<input checked="" type="checkbox"/>	Provencher SW and Glockner J, "Estimation of globular protein secondary structure from circular dichroism," <i>Biochemistry</i> 20(1):33-7 (1981)
<input checked="" type="checkbox"/>	Randall RE et al., "Purification of antibody-antigen complexes containing recombinant SIV proteins: comparison of antigen and antibody-antigen complexes for immune priming," <i>Vaccine</i> 12(4):351-8 (1994)
<input checked="" type="checkbox"/>	Riethmuller G et al., "Monoclonal antibodies in cancer therapy," <i>Curr Opin Immunol.</i> 5(5):732-9 (1993)
<input checked="" type="checkbox"/>	Riethmuller G et al., "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> 343(8907):1177-83 (1994)
<input checked="" type="checkbox"/>	Ron IG et al., "Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma," <i>Acta Obstet Gynecol Scand.</i> 73(8):658-62 (1994)
<input checked="" type="checkbox"/>	Roosnek E and A Lanzavecchia, "Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells," <i>J Exp Med.</i> 173(2):487-9 (1991)
<input checked="" type="checkbox"/>	Schlebusch H et al., "A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer," <i>Hybridoma</i> 14(2):167-7 (1995)
<input checked="" type="checkbox"/>	Schmolling J et al., "Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3," <i>Hybridoma</i> 14(2):183-6 (1995)

EXAMINER <i>Gary R. Schmitt</i>	DATE CONSIDERED <i>11/27/05 8/25/07</i>
------------------------------------	--

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Sect. For, PTO-1449 <b>INFORMATION DISCLOSURE IN AN APPLICATION</b> (Use several sheets if necessary)				Docket Number <b>107.823.129</b>	Application Number <b>09/376,604</b>
				Applicant <b>Madiyalakan et al.</b>	
Sheet	<b>7</b>	OF	<b>8</b>	Filing Date <b>August 18, 1999</b>	Group Art Unit <b>1642</b>

<i>CJ</i>	<i>HAC</i>	Schultes BC et al., "Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immunization with an anti-CA 125 (Mab OC125) monoclonal antibody by activation of the idiotypic network," <i>Eur J Clin Chem Clin Biochem.</i> 31(7):427-32 (1993)
	<input checked="" type="checkbox"/>	Sciammas R et al., "TCR gamma delta cells: mysterious cells of the immune system," <i>Immunol Res.</i> 13(4):268-79 (1994)
	<input checked="" type="checkbox"/>	Shitara K et al., "A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities," <i>Cancer Immunol Immunother.</i> 36(6):373-80 (1993)
	<input checked="" type="checkbox"/>	Spyder et al., <u>A Tabulation of Dose Equivalent per Microurie-Day for Source and Target Organs of an Adult for Various Radionuclides</u> Oak Ridge National Laboratory, Oak Ridge Tn (1975)
	<input checked="" type="checkbox"/>	Spalding BJ, "Few firms pursue anti-ids," <i>Bio/Technology</i> 10:950 (1992)
	<input checked="" type="checkbox"/>	Squire CM et al., "Antigen presentation is enhanced by targeting antigen to the Fc epsilon RII by antigen-anti-Fc epsilon RII conjugates," <i>J Immunol.</i> 152(9):4388-96 (1994)
	<input checked="" type="checkbox"/>	Stevenson FK and RE Hawkins, "Molecular Vaccines Against Cancer," <i>Immunologist</i> 2(1):16-19 (1994)
	<input checked="" type="checkbox"/>	Strieter RM et al., "Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline," <i>Biochem Biophys Res Commun.</i> 155(3):1230-6 (1988)
	<input checked="" type="checkbox"/>	Sulica A et al., "Regulation of human natural cytotoxicity by IgG. IV. Association between binding of monomeric IgG to the Fc receptors on large granular lymphocytes and inhibition of natural killer (NK) cell activity," <i>Cell Immunol.</i> 147(2):397-410 (1993)
	<input checked="" type="checkbox"/>	Taggart, RT, Samloff IM., "Stable antibody-producing murine hybridomas," <i>Science</i> 219:1228-1230 (1983)
	<input checked="" type="checkbox"/>	Tew JG et al., "Induction of the secondary antibody response: immune complex formation, iccosome release by follicular dendritic cells, processing and presentation of antigen by germinal center b cells and tingible body macrophages," <i>Progress in Leukocyte Biology</i> 7:1-10 Alan R Liss, Inc., New York (1988)
	<input checked="" type="checkbox"/>	Thomson AW and JV Forrester, "Therapeutic advances in immunosuppression," <i>Clin Exp Immunol.</i> 98(3):351-7 (1994)
	<input checked="" type="checkbox"/>	Torbett BE et al., "hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis," <i>Immunol Rev.</i> 124:139-64 (1991)
	<input checked="" type="checkbox"/>	Trauth BC et al., "Monoclonal antibody-mediated tumor regression by induction of apoptosis," <i>Science</i> 245(4915):301-5 (1989)
	<input checked="" type="checkbox"/>	Ullman EF et al., "Anti-immune complex antibodies enhance affinity and specificity of primary antibodies," <i>Proc Natl Acad Sci U S A.</i> 90(4):1184-9 (1993)
	<input checked="" type="checkbox"/>	United Nations, <i>Demographic Yearbook</i> , 1992 Forty-fourth issue, New York (1994)
	<input checked="" type="checkbox"/>	United Nations Population Fund, <i>The State of World Population</i> , 1991
	<input checked="" type="checkbox"/>	van der Bruggen P, "The long-standing quest for tumor rejection antigens," <i>Clin Immunol Immunopathol</i> 71(3):248-52 (1994)
	<input checked="" type="checkbox"/>	Vitetta ES and JW Uhr, "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy," <i>Cancer Res.</i> 54(20):5301-9 (1994)

EXAMINER <i>Gary M. Smith</i>	DATE CONSIDERED <i>7/27/05 8/20/05</i>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Subj. For, PTO-1449 <b>INFORMATION DISCLOSURE IN AN APPLICATION</b> (Use several sheets if necessary)				Docket Number <b>107.823.129</b>	Application Number <b>09/376,604</b>
				Applicant <b>Madiyalakan et al.</b>	
				Filing Date <b>August 18, 1999</b>	Group Art Unit <b>1642</b>
Sheet	<b>8</b>	OF	<b>8</b>		

<i>GW</i>	<i>MR</i>	Vose BM and Bonnard GD, "Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2," <i>Int J Cancer</i> 29(1):33-9 (1982)
		Wagner U, "Antitumor antibodies for immunotherapy of ovarian carcinomas," <i>Hybridoma</i> 12(5):521-8 (1993)
		Wagner U et al., "Clinical courses of patients with ovarian carcinomas after induction of anti-idiotypic antibodies against a tumor-associated antigen," <i>Tumor Diagnostic &amp; Therapeutic</i> 11:1-4 (1990)
		Wagner UA et al., "Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network," <i>Biotechnol Ther.</i> 3(1-2):81-9 (1992)
		Walker AM et al., "Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes," <i>Proc Natl Acad Sci U S A</i> 92(8):3278-82 (1995)
		Wawrzynczak EJ et al., "Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains," <i>Mol Immunol.</i> 29:213-20 (1992)
	<i>RW</i>	Weber D, <i>MIRD: Radiocuclide Data and Decay Schemes</i> New York: Society of Nuclear Medicine, 1989
		Wiersma EJ et al., "Enhancement of the antibody response to protein antigens by specific IgG under different experimental conditions," <i>Scand J Immunol.</i> 36(2):193-200 (1992)
		Wolff EA et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice," <i>Cancer Res.</i> 53(11):2560-5 (1993)
		Wyatt, PJ "Light scattering and the absolute characterization of macromolecules" Review, <i>Analytica Chimica Acta</i> 272:1-40 (1993)
		Xu ZY et al., "Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin," <i>Cancer Res.</i> 48(23):6658-63 (1988)
		Yano S et al., "Natural antibodies against the immunoglobulin F(ab')2 fragment cause elimination of antigens recognized by the F(ab')2 from the circulation," <i>Eur J Immunol.</i> 25(11):3128-33 (1995)
		Zhang S et al., "Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides," <i>Cancer Immunol Immunother.</i> 40(2):88-94 (1995)

diana havens - h:\chiu\_nancy\legal\docs\altarex\107823.129\altarexids 129.doc

EXAMINER <i>Jeanne J. Muller</i>	DATE CONSIDERED <i>8/20/07</i>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				<b>Complete If Known</b>	
				Application Number	09/376,604
				Filing Date	August 18, 1999
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1642
				Examiner Name	G. B. Nickol
Sheet	1	of	1	Attorney Docket Number	AREX-P03-004

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
GW	CA	JURNCIC-WINKLER et al., 1993, Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen, Eur. Urol. 1993;24(4):487-91	
	CB	PAUL, 1993, Fundamental Immunol., p. 1163	
	CC	SIMITSEK et al., 1995, Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants, J. Exp. Med. 181:1957-1963	
	CD	VRBA et al., 1975, Carcinoembryonic antigen: evidence for multiple antigenic determinants and isoantigens, Proc. Natl. Acad. Sci. USA 72(11):4602-4606	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>[Signature]</i>	Date Considered	8/20/07
			7/23/05

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

<b>Subst., Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number (Optional) <b>107.823.129</b>	Application Number <b>09/376,604</b>
	Applicant <b>MADIYALAKAN et al.</b>	
	Filing Date <b>August 18, 1999</b>	Group Art Unit <b>1642</b>

## U. S. Patent Documents

## FOREIGN PATENT DOCUMENTS


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

- MT HAC*

  - B1 Foon, K.A. et al., *Clinical Cancer Research*, Vol. 3, August 1997, "Clinical and Immune Responses In Advanced Colorectal Cancer Patients Treated with Anti-Idiotype Monoclonal Antibody Vaccine That Mimics the Carcinoembryonic Antigen", pp. 1267-1276.
  - B2 Uemura, H. et al., *Jpn J. Cancer Res.*, Vol. 7, No. 10, 1995, "Generation of anti-Idiotype antibodies related to prostatic specific antigen" (meeting abstract), p. 427
  - B3 Schultes, B.C. et al., *Cancer Immunol Immunother*, Vol. 46, No. 4, June 1998, "Anti-idiotype induction therapy: anti-CA125 antibodies (Ab<sub>y</sub>) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab<sub>x</sub>)", pp. 204-212.

EXAMINER <i>Mansfield</i>	DATE CONSIDERED 6-05-01 8/20/07
------------------------------	------------------------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

## **INFORMATION DISCLOSURE IN AN APPLICATION**

*(Use several sheets if necessary)*

Sheet 1 OF 1

Docket Number  
**107823.129**

**Application Number**  
**09/376,604**

Applicant  
Madiyalakan et al.

**Filing Date**

Group Art Unit

August 18, 1999

## **U.S. Patent Documents**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)**

MST	<u>Hart</u>	Hertel A et al. "A New Tc-99m Labeled Monoclonal Antibody (B43.13) Against CA 125 For Early Detection of Ovarian Cancer Recurrences – First Clinical Results" The Journal of Nuclear Medicine Abstract Book Vol. 33, Number 5 May 1992 p. 904, Abstract No. 338
MST	<u>White</u>	White E et al. "Process Validation for Virus Removal and Inactivation" BioPharm May 1991 pp. 34-39

EXAMINER 	DATE CONSIDERED 8/20/07 6-13-d1
---	---------------------------------------

**EXAMINER:** Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

**EXAMINER:** Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet

2

of

2

Complete If Known	
Application Number	09/376,604
Filing Date	August 18, 1999
First Named Inventor	Ragupathy Madiyalakan
Art Unit	1842
Examiner Name	G. B. Nickol
Attorney Docket Number	AREX-P03-004

KAC	CX	Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotypes," Nature, 272:265-66 (1978).	
KAC	CY	McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993).	
KAC	CZ	Paul, "Factors limiting effective tumor immunity", Fund. Immun., 1163-69 (1993).	
KAC	CA1	Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993).	
KAC	CB1	Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus Interleukin 4 and downregulated by tumor necrosis factor $\alpha$ ," J. Exp. Med., 179:1109-1118 (1994).	
KAC	CC1	Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991).	
KAC	CD1	Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 <sup>th</sup> Ed., 531-542 (1994).	
KAC	CE1	Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab')2 fragments," Imm. Letts., 27:39-44 (1991).	
KAC	CF1	Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997).	
KAC	CG1	Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65:406-412 (1996).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 3196605	/Karen A. Canella, Ph.D./	Date Considered	8/7/06 Karen A. Canella, Ph.
-------------------------------	---------------------------	-----------------	---------------------------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/376,604
Sheet	2	of	2	Filing Date	August 18, 1999
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1642
				Examiner Name	G. B. Nickol
				Attorney Docket Number	AREX-P03-004

KAC	CX	Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes," Nature, 272:265-66 (1978).	
KAC	CY	McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993).	
KAC	CZ	Paul, "Factors limiting effective tumor immunity", Fund. Immunol., 1163-69 (1993).	
KAC	CA1	Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993).	
KAC	CB1	Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor $\alpha$ ," J. Exp. Med., 179:1109-1118 (1994).	
KAC	CC1	Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991).	
KAC	CD1	Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 <sup>th</sup> Ed., 531-542 (1994).	
KAC	CE1	Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab')2 fragments," Imm. Letts., 27:39-44 (1991).	
KAC	CF1	Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997).	
KAC	CG1	Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65:406-412 (1996).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 3109985	/Karen A. Canella, Ph.D./	Date Considered	8/7/06
		/Karen A. Canella, Ph..	